Virpax Pharmaceuticals (VRPX) announced that it will effect a 1-for-25 reverse stock split of its common stock, par value $0.0001 per share that will become effective at 12:01 a.m. Eastern Time on March 20. The Company’s Common Stock will continue to trade on the Nasdaq Capital Market under the symbol “VRPX” and will begin trading on a split-adjusted basis when the Nasdaq opens on March 21. The new CUSIP number for the Common Stock following the reverse split will be 928251305.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRPX:
- Virpax receives positive Probudur results for dose range study
- Virpax Pharmaceuticals files to sell common stock and warrants, no amount given
- Biotech Alert: Searches spiking for these stocks today
- Virpax Pharmaceuticals reports Molecular Envelope Technology human study data
- Virpax Pharmaceuticals confirms results with U.S. Army with Probudur